Track topics on Twitter Track topics that are important to you
Following a unanimous vote by an FDA advisory panel against recommending approval of a new opioid, the company has withdrawn its NDA and announced it will make no further investment in the drug's development.
Medscape Medical News
Original Article: Opioid Dropped After Thumbs Down From FDA Advisory PanelNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...